Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens
By Victor Swezey
Eli Lilly is working with OpenAI to create new antimicrobials that are effective against drug-resistant pathogens.
The Indianapolis-based pharmaceutical company said that it will use the technology company's generative AI capabilities to treat antimicrobial resistance, which it called one of the greatest threats in public health and development.
Antimicrobial resistance occurs when pathogens stop responding to medicines over time, and can result from misuse or overuse of antimicrobials, according to Eli Lilly. The issue affects countries across the world but can be worsened by poverty and inequality.
Eli Lilly's Social Impact Venture Capital Portfolio in 2020 committed $100 million to the AMR Action Fund, with the goal of providing patients with two to four new antibiotics by 2030.
Write to Victor Swezey at victor.swezey@wsj.com
(END) Dow Jones Newswires
June 25, 2024 11:05 ET (15:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations